Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin Pharmaceutical Inc.

www.bmrn.com

Latest From BioMarin Pharmaceutical Inc.

Amarin Seeks EU Fast-Track For Potential Cardiovascular Blockbuster

Amarin’s cardiovascular risk reducing drug, Vascepa, is among four new products being considered for accelerated assessment by the European Medicines Agency.

Drug Review Europe

From Rare To Real: Pharma Urged To Act As China Preps New Rare Conditions List

Chinese regulatory agency working around the clock in preparation to release another official list of rare diseases, and a push to launch more innovative orphan drugs is underway. But this time pharma firms need to be more proactive, noted an NMPA official.

China Rare Diseases

Brineura Cleared By England's NICE For Ultra-Rare Batten Disease

NICE has recommended BioMarin’s Brineura for use in the National Health Service in England after a managed access deal and product pricing were agreed between BioMarin and NHS England. Final details of the deal are expected next month.

 

 

Health Technology Assessment Neurology

BioMarin's Brineura Pricing Deal Allows UK Market Access

More than two years after EU approval, BioMarin and the National Health Service have agreed pricing for the ultra-rare disease therapy, Brineura, allowing it to be publicly funded while further clinical data are collected as part of a managed access agreement.

 

Neurology Market Access
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register